These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18461809)

  • 1. [Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS].
    Galegov GA
    Antibiot Khimioter; 2007; 52(1-2):42-5. PubMed ID: 18461809
    [No Abstract]   [Full Text] [Related]  

  • 2. Lopinavir/ritonavir. (Kaletra).
    Res Initiat Treat Action; 2000 Dec; 6(4):16-8. PubMed ID: 11708169
    [No Abstract]   [Full Text] [Related]  

  • 3. [Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor].
    Ershov FI; Kas'ianova NV; Vasil'ev AN
    Antibiot Khimioter; 2002; 47(11):27-9. PubMed ID: 12698577
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-HIV agents. Using only lopinavir/ritonavir (Kaletra).
    TreatmentUpdate; 2008 Jan; 20(1):1-2. PubMed ID: 18320690
    [No Abstract]   [Full Text] [Related]  

  • 5. [Lopinavir/ritonavir monotherapy in the treatment of HIV infection. Introduction].
    Pulido Ortega F; Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():1. PubMed ID: 19572436
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
    TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
    [No Abstract]   [Full Text] [Related]  

  • 7. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.
    Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
    Kaplan SS; Hicks CB
    Expert Opin Pharmacother; 2005 Aug; 6(9):1573-85. PubMed ID: 16086645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A king in the CASTLE? Optimum initial HIV protease inhibitor.
    Torti C; Frank I
    Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849
    [No Abstract]   [Full Text] [Related]  

  • 10. [Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice].
    Moltó J; Clotet B
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 16():24-6. PubMed ID: 19572441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
    Kempf DJ; Isaacson JD; King MS; Brun SC; Sylte J; Richards B; Bernstein B; Rode R; Sun E
    Antivir Ther; 2002 Sep; 7(3):165-74. PubMed ID: 12487383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug interactions. Coming soon--a new formulation of Kaletra.
    TreatmentUpdate; 2006; 18(3):7. PubMed ID: 17209241
    [No Abstract]   [Full Text] [Related]  

  • 13. Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient.
    Conradie F; Sanne I; Venter W; Eron J
    AIDS; 2004 Apr; 18(7):1084-5. PubMed ID: 15096819
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug resistance test shows encouraging results.
    AIDS Alert; 2002 Feb; 17(2):17-8, 13. PubMed ID: 11862740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression.
    Chan-Tack KM; Edozien A
    J Acquir Immune Defic Syndr; 2006 Apr; 41(4):531-2. PubMed ID: 16652066
    [No Abstract]   [Full Text] [Related]  

  • 17. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
    Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
    HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.
    Resino S; Bellón JM; Muñoz-Fernández MA;
    J Antimicrob Chemother; 2006 Mar; 57(3):579-82. PubMed ID: 16446377
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.